NDAORALTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing three nucleoside reverse transcriptase inhibitors (NRTIs): lamivudine, zidovudine, and abacavir. It is indicated for the treatment of HIV-1 infection in adults and children. The combination works by inhibiting reverse transcriptase, blocking viral replication.
Pre-Launch
Pre-launch status suggests early-stage commercial planning with developing team infrastructure; expect roles in regulatory, market access, and launch readiness.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career prospects center on pre-launch execution and emerging-market commercial build-out for Aurobindo's HIV portfolio. Professionals will drive regulatory clearance, reimbursement strategy, and cost-competitive positioning in price-sensitive geographies where triple-NRTI therapy remains standard-of-care. This role emphasizes operational rigor, emerging market expertise, and lifecycle management over innovative medicine development.
Regulatory Affairs Manager
Worked on LAMIVUDINE; ZIDOVUDINE; ABACAVIR at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.